Authors
Latest:
Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and OncologyConflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
Latest:
Looking Ahead: What’s on the Horizon in Advanced MelanomaPanelists discuss how emerging advances in melanoma treatment include next-generation tumor-infiltrating lymphocyte therapy, oncolytic immunotherapy, bispecific antibodies, cancer vaccines, and neoadjuvant approaches that may allow de-escalation of both surgery and systemic therapy while improving treatment-free survival.
Latest:
Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and CancerHuman saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.
Latest:
Future Perspectives and Unmet Needs in CLLThe panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.
Latest:
Improving the RCC Patient Journey and Future Therapeutic DirectionsPanelists discuss areas for improvement in the RCC journey from the patient perspective, including the impact of emerging research on their experience, and explore therapeutic approaches and clinical research areas that show promise for improving outcomes in advanced RCC, with a focus on novel targets and mechanisms of action in development.
Latest:
Key Takeaways on Evolving Treatment Landscape in Multiple MyelomaThe expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.
Latest:
Brandon Sheffield, MD, Details NGS Benefits Vs Single-Gene Testing in NSCLCAt the 2022 WCLC, Brandon Sheffield, MD, presented data demonstrating the advantage of next-generation sequencing over other biomarker testing strategies in patients with non–small cell lung cancer.
Latest:
Supporting Patients Through Treatment for Advanced NSCLCPanelists discuss how dose modifications for ALK inhibitors can significantly improve quality of life issues like brain fog and weight gain while maintaining disease control, emphasizing the importance of multidisciplinary team support including palliative care from diagnosis.
Latest:
Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate CancerPanelists discuss how PSMA PET imaging is expected to evolve, enhancing precision in prostate cancer treatment through improved detection and staging. Medical professionals anticipate broader use in therapy guidance, with future advancements addressing gaps in early detection and metastasis, improving treatment strategies.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key TakeawaysPanelists discuss how UCSF Health has learned that successful integration of CAR T-cell therapy in multiple myeloma requires multidisciplinary collaboration, patient selection optimization, and management of toxicities. Future research includes exploring CAR T-cell therapy in earlier treatment lines and combining it with novel agents to enhance efficacy.
